Skip to main content
. 2023 Oct 3;101(14):e1391–e1401. doi: 10.1212/WNL.0000000000207663

Figure 2. Mixed-Models for Repeated Measures-Adjusted Change From Baseline in the Placebo and Semorinemab Treatment Arms, for the Coprimary and Secondary Efficacy Endpoints.

Figure 2

Coprimary efficacy endpoints: (A) ADAS-Cog11 and (B) ADCS-ADL. Secondary efficacy endpoints: (C) CDR-SB and (D) MMSE. Error bars represent 95% CIs. *p < 0.05, *** p < 0.001. In all other time points, the differences observed were not statistically significant. Weeks 0, 25, 37, and 49 time points include participants from cohort 1 and cohort 2, while week 61 time point includes only participants from cohort 2 (shown separate from cohort 1 and cohort 2 analyses). The numbers of participants in each dose arm assessed at each time point on each outcome measure are shown in the data beneath each graph. ADCS-ADL = Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale; ADAS-Cog-11 = Alzheimer's Disease Assessment Scale-Cognitive Subscale; CDR-SB = Clinical Dementia Rating-Sum of Boxes; MMSE = Mini-Mental State Examination.